# Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment

> **NCT04807257** · PHASE1,PHASE2 · RECRUITING · sponsor: **NanoRay Biotech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Malignant Fungating Wound

## Interventions

- **COMBINATION_PRODUCT:** Auger Molecular Therapy (AMT)

## Key facts

- **NCT ID:** NCT04807257
- **Lead sponsor:** NanoRay Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807257, "Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04807257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*